• Something wrong with this record ?

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

MJ. Morris, D. Castellano, K. Herrmann, JS. de Bono, ND. Shore, KN. Chi, M. Crosby, JM. Piulats, A. Fléchon, XX. Wei, H. Mahammedi, G. Roubaud, H. Študentová, J. Nagarajah, B. Mellado, Á. Montesa-Pino, E. Kpamegan, S. Ghebremariam, TN. Kreisl, C....

. 2024 ; 404 (10459) : 1227-1239. [pub] 20240915

Language English Country England, Great Britain

Document type Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc24018842
E-resources Online Full text

NLK ProQuest Central from 1992-01-04 to 3 months ago
Nursing & Allied Health Database (ProQuest) from 1992-01-04 to 3 months ago
Health & Medicine (ProQuest) from 1992-01-04 to 3 months ago
Family Health Database (ProQuest) from 1992-01-04 to 3 months ago
Psychology Database (ProQuest) from 1992-01-04 to 3 months ago
Health Management Database (ProQuest) from 1992-01-04 to 3 months ago
Public Health Database (ProQuest) from 1992-01-04 to 3 months ago

Links

PubMed 39293462
DOI 10.1016/s0140-6736(24)01653-2
Knihovny.cz E-resources

BACKGROUND: [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of 177Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer. METHODS: In this phase 3, randomised, controlled trial conducted at 74 sites across Europe and North America, taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who had progressed once on a previous ARPI were randomly allocated (1:1) to open-label, intravenous 177Lu-PSMA-617 at a dosage of 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles, or a change of ARPI (to abiraterone or enzalutamide, administered orally on a continuous basis per product labelling). Crossover from ARPI change to 177Lu-PSMA-617 was allowed after centrally confirmed radiographic progression. The primary endpoint was radiographic progression-free survival, defined as the time from randomisation until radiographic progression or death, assessed in the intention-to-treat population. Safety was a secondary endpoint. This study is registered with ClinicalTrials.gov (NCT04689828) and is ongoing. In this primary report of the study, we present primary (first data cutoff) and updated (third data cutoff) analyses of radiographic progression-free survival; all other data are based on the third data cutoff. FINDINGS: Overall, of the 585 patients screened, 468 met all eligibility criteria and were randomly allocated between June 15, 2021 and Oct 7, 2022 to receive 177Lu-PSMA-617 (234 [50%] patients) or ARPI change (234 [50%]). Baseline characteristics were mostly similar between groups; median number of 177Lu-PSMA-617 cycles was 6·0 (IQR 4·0-6·0). Of patients assigned to ARPI change, 134 (57%) crossed over to receive 177Lu-PSMA-617. In the primary analysis (median time from randomisation to first data cutoff 7·26 months [IQR 3·38-10·55]), the median radiographic progression-free survival was 9·30 months (95% CI 6·77-not estimable) in the 177Lu-PSMA-617 group versus 5·55 months (4·04-5·95) in the ARPI change group (hazard ratio [HR] 0·41 [95% CI 0·29-0·56]; p<0·0001). In the updated analysis at time of the third data cutoff (median time from randomisation to third data cutoff 24·11 months [IQR 20·24-27·40]), median radiographic progression-free survival was 11·60 months (95% CI 9·30-14·19) in the 177Lu-PSMA-617 group versus 5·59 months (4·21-5·95) in the ARPI change group (HR 0·49 [95% CI 0·39-0·61]). The incidence of grade 3-5 adverse events was lower in the 177Lu-PSMA-617 group (at least one event in 81 [36%] of 227 patients; four [2%] grade 5 [none treatment related]) than the ARPI change group (112 [48%] of 232; five [2%] grade 5 [one treatment related]). INTERPRETATION: 177Lu-PSMA-617 prolonged radiographic progression-free survival relative to ARPI change, with a favourable safety profile. For patients with PSMA-positive metastatic castration-resistant prostate cancer who are being considered for a change of ARPI after progression on a previous ARPI, 177Lu-PSMA-617 may be an effective treatment alternative. FUNDING: Novartis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018842
003      
CZ-PrNML
005      
20241024111117.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S0140-6736(24)01653-2 $2 doi
035    __
$a (PubMed)39293462
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Morris, Michael J $u Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: morrism@mskcc.org
245    10
$a 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial / $c MJ. Morris, D. Castellano, K. Herrmann, JS. de Bono, ND. Shore, KN. Chi, M. Crosby, JM. Piulats, A. Fléchon, XX. Wei, H. Mahammedi, G. Roubaud, H. Študentová, J. Nagarajah, B. Mellado, Á. Montesa-Pino, E. Kpamegan, S. Ghebremariam, TN. Kreisl, C. Wilke, K. Lehnhoff, O. Sartor, K. Fizazi, PSMAfore Investigators
520    9_
$a BACKGROUND: [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of 177Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer. METHODS: In this phase 3, randomised, controlled trial conducted at 74 sites across Europe and North America, taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who had progressed once on a previous ARPI were randomly allocated (1:1) to open-label, intravenous 177Lu-PSMA-617 at a dosage of 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles, or a change of ARPI (to abiraterone or enzalutamide, administered orally on a continuous basis per product labelling). Crossover from ARPI change to 177Lu-PSMA-617 was allowed after centrally confirmed radiographic progression. The primary endpoint was radiographic progression-free survival, defined as the time from randomisation until radiographic progression or death, assessed in the intention-to-treat population. Safety was a secondary endpoint. This study is registered with ClinicalTrials.gov (NCT04689828) and is ongoing. In this primary report of the study, we present primary (first data cutoff) and updated (third data cutoff) analyses of radiographic progression-free survival; all other data are based on the third data cutoff. FINDINGS: Overall, of the 585 patients screened, 468 met all eligibility criteria and were randomly allocated between June 15, 2021 and Oct 7, 2022 to receive 177Lu-PSMA-617 (234 [50%] patients) or ARPI change (234 [50%]). Baseline characteristics were mostly similar between groups; median number of 177Lu-PSMA-617 cycles was 6·0 (IQR 4·0-6·0). Of patients assigned to ARPI change, 134 (57%) crossed over to receive 177Lu-PSMA-617. In the primary analysis (median time from randomisation to first data cutoff 7·26 months [IQR 3·38-10·55]), the median radiographic progression-free survival was 9·30 months (95% CI 6·77-not estimable) in the 177Lu-PSMA-617 group versus 5·55 months (4·04-5·95) in the ARPI change group (hazard ratio [HR] 0·41 [95% CI 0·29-0·56]; p<0·0001). In the updated analysis at time of the third data cutoff (median time from randomisation to third data cutoff 24·11 months [IQR 20·24-27·40]), median radiographic progression-free survival was 11·60 months (95% CI 9·30-14·19) in the 177Lu-PSMA-617 group versus 5·59 months (4·21-5·95) in the ARPI change group (HR 0·49 [95% CI 0·39-0·61]). The incidence of grade 3-5 adverse events was lower in the 177Lu-PSMA-617 group (at least one event in 81 [36%] of 227 patients; four [2%] grade 5 [none treatment related]) than the ARPI change group (112 [48%] of 232; five [2%] grade 5 [one treatment related]). INTERPRETATION: 177Lu-PSMA-617 prolonged radiographic progression-free survival relative to ARPI change, with a favourable safety profile. For patients with PSMA-positive metastatic castration-resistant prostate cancer who are being considered for a change of ARPI after progression on a previous ARPI, 177Lu-PSMA-617 may be an effective treatment alternative. FUNDING: Novartis.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a nádory prostaty rezistentní na kastraci $x farmakoterapie $x patologie $7 D064129
650    12
$a heterocyklické sloučeniny monocyklické $x terapeutické užití $7 D006573
650    _2
$a senioři $7 D000368
650    12
$a lutecium $x terapeutické užití $7 D008187
650    12
$a androsteny $x terapeutické užití $7 D000736
650    12
$a dipeptidy $x terapeutické užití $7 D004151
650    12
$a fenylthiohydantoin $x terapeutické užití $7 D010669
650    12
$a nitrily $x terapeutické užití $7 D009570
650    _2
$a antagonisté androgenních receptorů $x terapeutické užití $7 D059002
650    _2
$a lidé středního věku $7 D008875
650    _2
$a benzamidy $x terapeutické užití $7 D001549
650    _2
$a taxoidy $x terapeutické užití $7 D043823
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a radionuklidy $x terapeutické užití $7 D011868
650    _2
$a doba přežití bez progrese choroby $7 D000077982
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Castellano, Daniel $u Medical Oncology Department, Hospital Universitario 12 de Octubre, I+12 Research Institute, Madrid, Spain
700    1_
$a Herrmann, Ken $u Department of Nuclear Medicine, University of Duisburg-Essen, German Cancer Consortium-University Hospital Essen, Essen, Germany; National Center for Tumor Diseases, NCT West, Heidelberg, Germany
700    1_
$a de Bono, Johann S $u The Institute of Cancer Research and The Royal Marsden Hospital, London, UK
700    1_
$a Shore, Neal D $u Carolina Urologic Research Center, AU Clinics, Myrtle Beach, SC, USA
700    1_
$a Chi, Kim N $u BC Cancer, Vancouver, BC, Canada
700    1_
$a Crosby, Michael $u Veterans Prostate Cancer Awareness, San Diego, CA, USA
700    1_
$a Piulats, Josep M $u Catalan Institute of Oncology, Barcelona, Spain
700    1_
$a Fléchon, Aude $u Centre Léon-Bérard, Lyon, France
700    1_
$a Wei, Xiao X $u Dana-Farber Cancer Institute, Boston, MA, USA
700    1_
$a Mahammedi, Hakim $u Centre Jean Perrin, Clermont-Ferrand, France
700    1_
$a Roubaud, Guilhem $u Institut Bergonié, Bordeaux, France
700    1_
$a Študentová, Hana $u Department of Oncology, Palacký University, Faculty of Medicine and Dentistry, University Hospital, Olomouc, Czech Republic
700    1_
$a Nagarajah, James $u Radboud University Medical Centre, Nijmegen, Netherlands; Roentgeninstitut Düsseldorf, Düsseldorf, Germany
700    1_
$a Mellado, Begoña $u Medical Oncology Department, Hospital Clínic de Barcelona, Institut d' Investigacions Biomèdiques Pi i Sunyer, University of Barcelona, Barcelona, Spain
700    1_
$a Montesa-Pino, Álvaro $u UGCI Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, IBIMA, Málaga, Spain
700    1_
$a Kpamegan, Euloge $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Ghebremariam, Samson $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Kreisl, Teri N $u Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
700    1_
$a Wilke, Celine $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Lehnhoff, Katja $u Novartis Pharma AG, Basel, Switzerland
700    1_
$a Sartor, Oliver $u Mayo Clinic, Rochester, MN, USA
700    1_
$a Fizazi, Karim $u Gustave Roussy Institute, Paris-Saclay University, Paris, France
710    2_
$a PSMAfore Investigators
773    0_
$w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 404, č. 10459 (2024), s. 1227-1239
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39293462 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111111 $b ABA008
999    __
$a ok $b bmc $g 2201607 $s 1230815
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 404 $c 10459 $d 1227-1239 $e 20240915 $i 1474-547X $m Lancet (London, England) $n Lancet $x MED00010161
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Archiving options